ArticleBMC cancer2026
Establishment of a microbial abundance prognostic model for colorectal cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPrevious studies have demonstrated a close association between gut microbiota and the onset and progression of colorectal cancer (CRC). However, the prognostic and therapeutic value of microbiota in CRC remains controversial. This study integrates multiomics approaches to investigate the prognostic and therapeutic implications of microbiota in CRC.
methodsA CRC microbial abundance prognostic model (MAPM) was constructed utilizing bioinformatics approaches to evaluate its prognostic value. The relationship between MAPM and the clinical characteristics of CRC, as well as the immune microenvironment, was analyzed. Furthermore, key prognostic genes associated with the MAPM were identified and validated in vitro and in vivo assays.
resultsThe MAPM comprised 12 microbes and effectively stratified the prognosis of CRC patients. The risk score of this model exhibits a close association with the immune infiltration of CRC. Remarkably, HSF4, identified as a key gene from the MAPM, is found to be overexpressed in the tumor tissues, and its high expression independently predicts poor prognosis in CRC patients. Knockdown of HSF4 significantly inhibits the proliferation, colony formation, migration, and invasion of CRC cells in vitro, as well as the growth of xenografts in nude mice.
conclusionA MAPM is established to predict the prognosis of CRC patients, further highlighting the potential of detecting the microbiome in clinical practice. Moreover, HSF4, as a prognostic gene from the MAPM, is a promising drug target for CRC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.